Article
Profilin 1 is a potential biomarker for bladder cancer aggressiveness.
Biotechnology Division, Biomedical Research Foundation, Academy of Athens, Greece.
Molecular & Cellular Proteomics (impact factor:
7.4).
12/2011;
11(4):M111.009449.
DOI:10.1074/mcp.M111.009449
pp.M111.009449
Source: PubMed
- Citations (1)
-
Cited In (0)
-
Article: Searching for serum tumor markers for colorectal cancer using a 2-D DIGE approach.
[show abstract] [hide abstract]
ABSTRACT: Identification of specific protein markers for colorectal cancer (CRC) could provide a basis for its early diagnosis and detection, as well as clues to the molecular mechanisms governing cancer progression. In the present study, 2-D DIGE coupled with MS was used to screen for biomarker candidates in the serum proteome of ten human CRC samples and ten healthy control samples. After pooling identical amounts of serum proteins (based on total protein concentration), albumin/IgG was depleted under partially denaturing conditions. Subsequently, the serum samples were labeled with three different CyDyes, and separated by 2-D DIGE. After analysis with the biological variation analysis module of the DeCyder software, only three spots were found to be significantly elevated in all patient groups (with ratios from 1.52 to 9.08), whereas five spots were significantly down-regulated in patients (with ratios from -1.23 to -10.21) (t-test; p<0.05). Finally, two potential biomarkers, Transaldolase 1 and thyroid receptor interactor, were chosen for validation and analysis by ELISA with the serum of 30 CRC patients and 30 healthy controls. The serum levels of the two proteins correlated well with the 2-D DIGE results. Thus, 2-D DIGE approaches show great promise for biomarker discovery in CRC.Electrophoresis 07/2009; 30(15):2591-9. · 3.30 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
aggressive BC
BC stratification
benign controls
biomarker discovery
disease aggressiveness
Elisa analysis
eluted proteins analyzed
fractionation strategy
identified proteins
immobilized metal affinity chromatography
immobilized metal affinity chromatography fractionation
low amounts
multiple proteins
non invasive BC
occasional expression
poor prognosis
profilin 1
tissue microarray analysis
urinary proteins
Urine samples